Trends in Cardiovascular Medicine
Volume 16, Issue 5 , Pages 156-162 , July 2006

The Nonlipid Effects of Statins on Endothelial Function

  • Joshua A. Beckman
    • ,
  • Mark A. Creager

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Mark A. Creager, MD, Cardiovascular Division, 75 Francis Street, Boston, MA 02115, USA. Tel.: (+1) 617-732-5267; fax: (+1) 617-232-2749.

References 

  1. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64–70
  2. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation. 2004;110:880–885
  3. Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488–493
  4. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995;26:1235–1241
  5. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
  6. Beckman JA, Goldfine AB, Gordon MB, et al. Oral antioxidant therapy improves endothelial function in type 1 but not type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol. 2003;285:H2392–H2398
  7. Beckman JA, Liao JK, Hurley S, et al. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res. 2004;95:217–223
  8. Brouet A, Sonveaux P, Dessy C, et al. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res. 2001;89:866–873
  9. Casey PJ. Protein lipidation in cell signaling. Science. 1995;268:221–225
  10. Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol. 2004;57:640–651
  11. Cortellaro M, Cofrancesco E, Arbustini E, et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost. 2002;88:41–47
  12. Dalla Nora E, Passaro A, Zamboni PF, et al. Atorvastatin improves metabolic control and endothelial function in type 2 diabetic patients: a placebo-controlled study. J Endocrinol Invest. 2003;26:73–78
  13. Dangas G, Badimon JJ, Smith DA, et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol. 1999;33:1294–1304
  14. Dichtl W, Dulak J, Frick M, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23:58–63
  15. Dimitrova Y, Dunoyer-Geindre S, Reber G, et al. Effects of statins on adhesion molecule expression in endothelial cells. J Thromb Haemost. 2003;1:2290–2299
  16. Dogra GK, Watts GF, Herrmann S, et al. Statin therapy improves brachial artery endothelial function in nephrotic syndrome. Kidney Int. 2002;62:550–557
  17. Dogra GK, Watts GF, Chan DC, Stanton K. Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria. Diabet Med. 2005;22:239–242
  18. Economides PA, Caselli A, Tiani E, et al. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab. 2004;89:740–747
  19. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998;95:8880–8885
  20. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420:629–635
  21. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 2001;103:113–118
  22. Gaugler MH, Vereycken-Holler V, Squiban C, et al. Pravastatin limits endothelial activation after irradiation and decreases the resulting inflammatory and thrombotic responses. Radiat Res. 2005;163:479–487
  23. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 1999;34:1281–1286
  24. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425–430
  25. Gonzalez-Fernandez F, Jimenez A, Lopez-Blaya A, et al. Cerivastatin prevents tumor necrosis factor-alpha-induced downregulation of endothelial nitric oxide synthase: role of endothelial cytosolic proteins. Atherosclerosis. 2001;155:61–70
  26. Hattori Y, Nakanishi N, Akimoto K, et al. HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:176–182
  27. Hermann F, Forster A, Chenevard R, et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol. 2005;45:461–464
  28. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711–2719
  29. Hernandez-Perera O, Perez-Sala D, Soria E, Lamas S. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res. 2000;87:616–622
  30. Jimenez A, Arriero MM, Lopez-Blaya A, et al. Regulation of endothelial nitric oxide synthase expression in the vascular wall and in mononuclear cells from hypercholesterolemic rabbits. Circulation. 2001;104:1822–1830
  31. John S, Delles C, Jacobi J, et al. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol. 2001;37:1351–1358
  32. Kalinowski L, Dobrucki IT, Malinski T. Cerivastatin potentiates nitric oxide release and eNOS expression through inhibition of isoprenoids synthesis. J Physiol Pharmacol. 2002;53:585–595
  33. Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108:1560–1566
  34. Koh KK, Son JW, Ahn JY, et al. Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2002;22:e19–e23
  35. Kothe H, Dalhoff K, Rupp J, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation. 2000;101:1760–1763
  36. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004–1010
  37. Lacut K, Oger E, Le Gal G, et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundam Clin Pharmacol. 2004;18:477–482
  38. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998;273:24266–24271
  39. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 1997;272:31725–31729
  40. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129–1135
  41. Laufs U, Endres M, Custodis F, et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation. 2000;102:3104–3110
  42. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002;110:285–288
  43. Lusis AJ. Atherosclerosis. Nature. 2000;407:233–241
  44. Marchioli R, Marfisi RM, Carinci F, Tognoni G. Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease. Arch Intern Med. 1996;156:1158–1172
  45. Masamura K, Oida K, Kanehara H, et al. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho Family. Arterioscler Thromb Vasc Biol. 2003;23:512–517
  46. Mason RP, Walter MF, Day CA, Jacob RF. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol. 2005;96:11F–23F
  47. Molloy KJ, Thompson MM, Schwalbe EC, et al. Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively. Am J Cardiol. 2004;94:144–146
  48. Moncada S, Higgs A. The l-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002–2012
  49. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)—can C-reactive protein be used to target statin therapy in primary prevention?. Am J Cardiol. 2006;97:33–41
  50. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  51. Mueck AO, Seeger H, Lippert TH. Fluvastatin reduces endothelin secretion of cultured human umbilical vein endothelial cells. Eur J Clin Pharmacol. 1999;55:625–626
  52. Mullen MJ, Wright D, Donald AE, et al. Atorvastatin but not l-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J Am Coll Cardiol. 2000;36:410–416
  53. Nakamura T, Ushiyama C, Hirokawa K, et al. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol. 2001;21:449–454
  54. Nawawi H, Osman NS, Yusoff K, Khalid BA. Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia. Horm Metab Res. 2003;35:479–485
  55. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071–1080
  56. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126–1131
  57. Omi H, Okayama N, Shimizu M, et al. Statins inhibit high glucose-mediated neutrophil-endothelial cell adhesion through decreasing surface expression of endothelial adhesion molecules by stimulating production of endothelial nitric oxide. Microvasc Res. 2003;65:118–124
  58. Omori H, Nagashima H, Tsurumi Y, et al. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Br J Clin Pharmacol. 2002;54:395–399
  59. Orem C, Uydu HA, Yilmaz R, et al. The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients. Jpn Heart J. 2004;45:977–987
  60. Ostadal P, Alan D, Hajek P, et al. The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. Mol Cell Biochem. 2003;246:45–50
  61. Ozaki K, Yamamoto T, Ishibashi T, et al. Regulation of endothelial nitric oxide synthase and endothelin-1 expression by fluvastatin in human vascular endothelial cells. Jpn J Pharmacol. 2001;85:147–154
  62. Perticone F, Ceravolo R, Maio R, et al. Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients. Atherosclerosis. 2000;152:511–518
  63. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352:2184–2192
  64. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349–1357
  65. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  66. Rasmussen LM, Hansen PR, Nabipour MT, et al. Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem J. 2001;360:363–370
  67. Ray KK, Cannon CP. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?. Am J Cardiol. 2005;96:54F–60F
  68. Ray JG, Mamdani M, Tsuyuki RT, et al. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med. 2001;161:1405–1410
  69. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565
  70. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28
  71. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol. 2005;46:1855–1862
  72. Romano M, Mezzetti A, Marulli C, et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Investig Med. 2000;48:183–189
  73. Sadeghi MM, Collinge M, Pardi R, Bender JR. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J Immunol. 2000;165:2712–2718
  74. Sakabe K, Fukuda N, Wakayama K, et al. Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia. Am J Cardiol. 2004;94:497–500
  75. Schmidt A, Goepfert C, Feitsma K, Buddecke E. Lovastatin-stimulated superinduction of E-selectin, ICAM-1 and VCAM-1 in TNF-alpha activated human vascular endothelial cells. Atherosclerosis. 2002;164:57–64
  76. Sebestjen M, Zegura B, Keber I. Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia. J Intern Med. 2002;251:77–85
  77. Sen-Banerjee S, Mir S, Lin Z, et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation. 2005;112:720–726
  78. Shi J, Wang J, Zheng H, et al. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis. 2003;14:575–585
  79. Shishehbor MH, Aviles RJ, Brennan ML, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA. 2003;289:1675–1680
  80. Strey CH, Young JM, Molyneux SL, et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis. 2005;179:201–206
  81. Sugano R, Matsuoka H, Haramaki N, et al. Polymorphonuclear leukocytes may impair endothelial function: results of crossover randomized study of lipid-lowering therapies. Arterioscler Thromb Vasc Biol. 2005;25:1262–1267
  82. Toutouzas K, Vaina S, Tsiamis E, et al. Detection of increased temperature of the culprit lesion after recent myocardial infarction: the favorable effect of statins. Am Heart J. 2004;148:783–788
  83. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481–487
  84. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin Depresses Blood Clotting by Inhibiting Activation of Prothrombin, Factor V, and Factor XIII and by Enhancing Factor Va Inactivation. Circulation. 2001;103:2248–2253
  85. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol. 2005;25:287–294
  86. Wagner AH, Kohler T, Ruckschloss U, et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000;20:61–69
  87. Wang HR, Li JJ, Huang CX, Jiang H. Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta. 2005;353:53–60
  88. Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001;37:1450–1457
  89. Wassmann S, Faul A, Hennen B, et al. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res. 2003;93:e98–e103

PII: S1050-1738(06)00046-6

doi: 10.1016/j.tcm.2006.03.003

Trends in Cardiovascular Medicine
Volume 16, Issue 5 , Pages 156-162 , July 2006

Article Tools

* Image Usage & Resolution